AcelRx 'Reenergized' By EU Zalviso Approval; Royalty Sell-Off To Fund US Fight Back
This article was originally published in Scrip
AcelRx Pharmaceuticals Inc., which suffered a major setback last year when the US FDA refused to approve its lead product Zalviso (sufentanil sublingual tablets) for the treatment of post-operative pain, has been 'reenergized' by news that the product has been approved in Europe, management told Scrip. This follows news from earlier this week that AcelRx has sold the majority of the expected royalty stream from the sales of Zalviso in the EU to PDL BioPharma. AcelRx's commercial partner in the EU is Grunenthal GmbH.
Register for our free email digests: